• home
• Intact: C-terminal fragment FGF23 ratios explained

Why is it important to measure the ratio of active intact and inactive C-terminal FGF23 fragments?

FGF23 is an endocrine hormone regulating phosphate homeostasis by modulating renal phosphate reabsorption, vitamin D metabolism and parathyroid hormone (PTH) secretion. Epidemiological data suggests that higher FGF23 concentrations are associated with all-cause mortality, cardiovascular mortality, a higher risk of myocardial infarction, stroke and heart failure.

Levels of FGF23 and intact: C-terminal fragment FGF23 ratios can be altered in both genetic and acquired diseases. A primary excess in circulating intact FGF23 is the underlying cause of diseases like XLH, ADHR/ARHR or tumor-induced osteomalacia. The excessive FGF23 levels in these diseases cause renal phosphate wasting, low active vitamin D concentrations and defective mineralization of bones. By contrast, during iron deficiency FGF23 synthesis and cleavage are upregulated in a coupled manner, resulting in normal levels of intact FGF23 and high levels of cFGF23.

Therefore, different conditions result in varying characteristic iFGF23:cFGF23 ratios.

For more information on why iFGF23:cFGF23 ratios differ between diseases check out “Coupling Fibroblast Growth Factor 23 Production and Cleavage: Iron Deficiency, Rickets, and Kidney Disease” or check out out iFGF23 and cFGF12 ELISA.

Periostin functions as a ligand for integrins to support adhesion and migration of tumor cells which leads to increased cell survival, invasion, angiogenesis and metastasis in different cancer types including breast cancer (BC).
In a recent study using the Biomedica Human Periostin ELISA, Periostin levels were significantly increased in women with primary, non-metastatic breast cancer over 60 as well as in postmenopausal women. No difference was observed in patients with and without the presence of disseminated tumor cells. However, high levels of circulating Periostin were associated with a poorer BC specific survival. These results warrant further studies on the role of Periostin in cancer patients.

More information on the Biomedica Periostin assays can be found here.
Hoffman et al. High circulating levels of Periostin are associated with a poor survival in primary, non-metastatic breast cancer patients. Am Ass Cancer Res 2019; 79(4 Suppl):Abstract nr P6-09-08

C4d has been regarded as an indirect footprint of an antibody-mediated response against an allograft. While C4d has emerged as a potential marker for antibody-mediated-rejection (AMR) after transplantation over the last decade, its use as a prognostic tool is still under debate.

A recent study has shown a positive association of C4d with cardiac allograft vasculopathy and death in heart transplant recipients. Late C4d positivity (> 1-year post-transplant) demonstrated an even higher risk for developing cardiac allograft vasculopathy and poor prognosis than early C4d positivity (within 1 year). The authors of the study suggest a prognostic role for C4d in heart transplantation warranting routine long-term detection of this marker in the pathologic evaluation of cardiac AMR.

Biomedica’s Anti C4d Antibodies allow the identification of human complement split product C4d in paraffin and frozen sections, and by flow cytometry.

Husain et al. Routine C4d immunohistochemistry in cardiac allografts: Long-term outcomes. J Heart Lung Transplant 2017: 36(12):1329-1335

Check out the Biomedica anti-C4d antibodies for ICH and FITC.

FGF23 (Fibroblast Growth Factor 23), a well-known marker for phosphate metabolism, has achieved independent significance in the cardiovascular system [1]. Several large-scale prospective studies have established FGF23 as an independent risk marker for heart failure and mortality [2,3]. There is also growing evidence that FGF-23 levels can predict the response to therapies aimed to reduce heart failure risk [4].

FGF23 is expressed in the heart and is significantly elevated in heart failure

Recent studies indicate that FGF23 is also expressed in the heart [5]. It is significantly enhanced in clinical and experimental settings of cardiac remodeling and heart failure independent of renal function [6, 10]. Secreted by cardiac myocytes, FGF23 can stimulate pro-fibrotic factors in myocytes to induce fibrosis-related pathways in fibroblasts and consequently cardiac fibrosis. While acting on cardiac myocytes, FGF23 directly induces pro-hypertrophic genes and promotes the progression of LVH (left ventricular hypertrophy) in an autocrine and paracrine fashion. Thus, enhanced FGF23 may promote cardiac injury in various clinical settings by endocrine and paracrine/autocrine mechanisms [7].

FGF23 measurement for prognosis and risk assessment in heart failure

Several large-scale prospective studies show a linear correlation between FGF23 levels and mortality risk, particularly because of LVH and systolic heart insufficiency (heart failure with reduced ejection fraction, HFREF) [2,8]. This clinically evident association between HFREF and FGF23, is likely explained by FGF23 ‘s direct cardiotoxic effects on cardiomyocytes.  

Besides the known risk markers in HFREF patients such as serum sodium and BNP, the measurement of FGF23 can thus be of considerable use for risk stratification of individual patients. Of special relevance is the growing evidence that FGF23 levels can predict the response to a therapy with a blocker of the renin-angiotensin-aldosterone system [9].

Cardiovascular risk assessment under ACE therapy

In the PEACE Study (Prevention of Events With Angiotensin-Converting Enzyme) FGF23 was determined in 3,627 patients with stable ischemic heart disease (SIHD) [4]. Increased FGF23 levels correlated, with mortality rate and heart failure, but also identified those patients who benefitted significantly from treatment with ACE inhibitor. This effect was independent of renal function. These results indicate that FGF23 may become an attractive tool for individualized HFREF therapy. Patients with cardiorenal syndrome (combined heart and kidney failure) may benefit from FGF23 determination for estimation of individual risk and initiation of individualized treatment.

FGF23 and therapy monitoring

Patients with kidney disease show elevated serum concentrations of FGF23, associated with cardiovascular and all-cause mortality. A therapeutic approach to reduce increased FGF23 levels is the administration of (calcium-free) phosphatebinders (calcimimetics).  The „EVOLVE“ study (2,985 patients receiving hemodialysis with secondary Hyperparathyroidism), demonstrated that treatment-induced reductions in serum FGF23 were associated with lower rates of cardiovascular death and major cardiovascular events. Among patients randomized to cinacalcet, a ≥30% reduction in serum FGF23 between baseline and week 20 was associated with a reduction in the relative hazard of the clinically relevant end point, cardiovascular mortality, sudden cardiac death, and heart failure [9].

Further studies on FGF23

Clearly more experimental and clinical studies are required to justify integrating routine measurement of FGF23 as risk marker for heart failure or to guide treatment. However, it is one of the few promising biomarkers that has high potential to ascertain the effect of FGF23 specific therapeutic interventions on clinically relevant endpoints [10].

Literature

[1] Hu MG, Shiizaki K, Kuro-o M, Moe OW. Fibroblast Growth Factor 23 and Klotho: Physiology and Pathophysiology of an Endocrine Network of Mineral Metabolism. Annu Rev Physiol. 2013;75:503-33.
[2] Brandenburg VM, Kleber ME, Vervloet MG, Tomaschitz A, Pilz S, Stojakovic T, Delgado G, Grammer TB, Marx N, März W, Scharnagl H. Fibroblast growth factor 23(FGF23) and mortality: the Ludwigshafen Risk and Cardiovascular Health Study. Atherosclerosis. 2014 Nov;237(1):53-9.
[3] Olauson H, Vervloet MG, Cozzolino M, Massy ZA, Ureña Torres P, Larsson TE. New insights into the FGF23-Klotho axis. Semin Nephrol. 2014 Nov;34(6):586-97.
[4] Udell JA, Morrow DA, Jarolim P, Sloan S, Hoffman EB, O’Donnell TF, Vora AN,Omland T, Solomon SD, Pfeffer MA, Braunwald E, Sabatine MS. Fibroblast growth factor-23, cardiovascular prognosis, and benefit of angiotensin-converting enzyme inhibition in stable ischemic heart disease. J Am Coll Cardiol. 2014 Jun 10;63(22):2421-8
[5] Itoh N, Ohta H, Nakayama Y, Konishi M. Roles of FGF signals in heart development, health, and disease. Front Cell Dev Biol (2016) 4:110. doi:10.3389/fcell.2016.00110.
[6] Andrukhova O, Slavic S, Odorfer KI, Erben RG. Experimental myocardial infarction upregulates circulating fibroblast growth factor-23. J Bone Miner Res (2015) 30:1831–9. doi:10.1002/jbmr.2527.
[7] Leifheit-Nestler M and Haffner D. Paracrine effects of FGF23 on the Heart. Frontiers in Endocrinology | www.frontiersin.org May 2018 | Volume 9 | Article 278.
[8] Almahmoud MF, Soliman EZ, Bertoni AG, Kestenbaum B, Katz R,  Lima JAC, Ouyang P, Miller PE, Michos ED, Herrington DM; Fibroblast Growth Factor-23 and Heart Failure With Reduced Versus Preserved Ejection Fraction: MESA. J Am Heart Assoc. 2018 Sep 18;7(18):e008334.
[9] Moe SM, Chertow GM, Parfrey PS, Kubo Y, Block GA, Correa-Rotter R, Drüeke TB, Herzog CA, London GM, Mahaffey KW, Wheeler DC, Stolina M, Dehmel B, Goodman WG, Floege J; For the Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial Investigators. Cinacalcet, Fibroblast Growth Factor-23, and Cardiovascular Disease in Hemodialysis: The Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial. Circulation. 2015 July;132(1):27-39
[10] Vervloet  M; Renal and Extrarenal Effects of Fibroblast Growth Factor 23. Nature Reviews. Nephrology 15, Nr. 2 (Februar 2019): 109–20.

 

Read more on our fully validated and CE marked FGF-23 (intact) ELISA and FGF-23 (C-terminal) multi-matrix ELISA for IVD use.

Features and Benefits

• RELIABLE and FULLY VALIDATED for plasma samples – according to ICH Q2
• FAST ONE-STEP ELISA – only 3.5 h total incubation time
• PLASMA-BASED STANDARDS and CONTROLS INCLUDED – for biologically reliable data
• CHARACTERIZED MONOCLONAL ANTIBODIES – high specificity and sensitivity guaranteed
• COMPARABLE RESULTS – correlates with existing methods

Sepsis-associated encephalopathy (SAE) has significant impact on the neurocognitive outcome of sepsis survivors. Biomarkers of brain injury and inflammation could help monitor encephalopathy in patients with sepsis.  

Levels of NT-proCNP, a protein which is released during systemic inflammation, are highly elevated in both the plasma and CSF of sepsis patients with SAE. Since NT-proCNP levels in CSF and plasma NT-proCNP are highly correlated, plasma NT-proCNP might be a useful proxy biomarker to predict the emergence of SAE during the early phase of sepsis and detect neurological impairment at the later stages of the disease.  

Plasma NT-proCNP measurement might be superior to S100B and NSE in SAE.

Ehler et al. Diagnostic value of NT-proCNP compared to NSE and S100B in cerebrospinal fluid and plasma of patients with sepsis-associated encephalopathy. Neurosci Lett. 2019;692:167-173.

For more information on the Biomedica NT-proCNP ELISA check out: https://www.bmgrp.com/product/cardiovascular/biomedica-nt-procnp-elisa/  

Spinal cord injury (SCI) induces an acute alteration in bone metabolism. Although the aetiology of the bone disturbances is not precisely known, immobilisation reduces mechanical loading and the morphology of osteocytes, which are the primary mechanosensors. Periostin and Sclerostin are secreted mostly by osteocytes and are involved in bone’s mechanical response.

In a recent study using the Biomedica Periostin ELISA and Sclerostin ELISA, individuals with spinal cord injury presented higher serum Periostin levels in the acute phase and normal values in the chronic phase.

Conversely, serum Sclerostin levels were suppressed whatever the post-injury duration in the individuals with spinal cord injury. Paraplegia vs. tetraplegia and fragility fracture status seemed to influence Sclerostin levels only.

Maïmoun et al. Periostin and Sclerostin levels in individuals with spinal cord injury and their relationship with bone mass, bone turnover, fracture and osteoporosis status. Bone. 2019 127:612-619.

Vanin1 is a glycoprotein which is selectively expressed in renal tubular cells.

Urinary Vanin1 is a biomarker for the prediction of drug induced acute kidney injury. Compared with KIM-1 and NGAL, Vanin-1 has shown superior value in AKI detection. It can also help in the detection and monitoring of obstructive nephropathy.

Vanin-1 is a marker for the early detection of acute kidney injury

At Biomedica, we offer the FIRST fully validated VANIN-1 (urine) ELISA. Our quick, one-step ELISA is optimized for human urine samples and rigorously validated according to FDA/ICH/EMEA guidelines. 

Check out the Vanin-1 ELISA validation data

 

Related literature:

Urinary Vanin-1 As a Novel Biomarker for Early Detection of Drug-Induced Acute Kidney Injury 
Hosohata K et al., J Pharmoc Exp Therapeut, 2012

A Novel Biomarker for Acute Kidney Injury, Vanin-1, for Obstructive Nephropathy: A Prospective Cohort Pilot Study
Washino S. et al., Int J Mol Sci, 2019 

Abstract

First commercially available fully validated ELISA to reliably measure Vanin-1 in human urine samples from Biomedica.

Vanin-1 is a glycoprotein that is selectively expressed in renal tubular cells.

Urinary Vanin-1

• has as superior predictive value for drug induced AKI than KIM-1 or NGAL
  
  
• is a novel biomarker to detect and monitor the clinical course of obstructive nephropathy
  

Biomedica offers the FIRST fully validated VANIN-1 (urine) ELISA for reliable results

Try our  VANIN-1 (urine) ELISA  and contact us for your evaluation discount.

Related Literature & Findings:

Urinary Vanin-1 As a Novel Biomarker for Early Detection of Drug-Induced Acute Kidney Injury. Hosohata K et al., J Pharmoc Exp Therapeut, 2012; 656–62.

A Novel Biomarker for Acute Kidney Injury, Vanin-1, for Obstructive Nephropathy: A Prospective Cohort Pilot Study. Washino S. et al., Int J Mol Sci, 2019; 20, 4.

Pharmacological inhibition of Vanin-1 is not protective in models of acute and chronic kidney disease. Unterschemmann K, Ehrmann A, Herzig I, Andreevski AL, Lustig K, Schmeck C, Eitner F, Grundmann M. Am J Physiol Renal Physiol. 2021 Jan 1;320(1):F61-F73. doi: 10.1152/ajprenal.00373.2020. Epub 2020 Nov 16. PMID: 33196323.

Abstract

BI-VAN1U –  human VANIN-1 ELISA Assay Highlights:

√  Optimized for human urine samples

√  Highly SPECIFIC and DEFINED characterized antibodies

√   RELIABLE rigorously validated according to FDA/ICH/EMEA guidelines

√   QUICK one-step ELISA

Related products:

Nephrology: FGF23, Endostatin, Anti C4d
Cardiology: NT-proBNP, Endothelins, proANP, NT-proCNP

Meet us at the ASBMR in Orlando at

1. The Biomedica booth # 516
   
   
2. Our Posters: #SUN-103, #SUN-271, #MON-252 and #MON-331
   
   
3. The Bone Turnover Markers Working Group 
   Room# W307B, Sept 20 at 7:30pm
   
   
4. Diurnal Changes in Serum Levels of Bone-Related Circulating MicroRNAs. 
   Oral presentation #1140, room# W314, Monday, Sept 23 from 2:15pm-2:30pm
   
   

If you cannot make it to the ASBMR contact us for your special quote.

Biomedica is proud to announce the launch of its CE-marked FGF23 (intact) human ELISA, cat# BI-20700

Features and Benefits

• RELIABLE & FULLY VALIDATED for plasma samples – according to ICH Q2

• SERUM, URINE and CC SUPERNATANT are compatible with this ELISA

• FAST ONE-STEP ELISA – only 3.5 h total incubation time

• PLASMA BASED STANDARDS and CONTROLS INCLUDED – for biologically reliable data

• CHARACTERIZED MONOCLONAL RECOMBINANT ANTIBODIES – high specificity guaranteed

The new intact FGF23 ELISA was mentioned in the most recent Biocompare newsletter as a featured product. Check out the drug discovery and development newsletter to learn more.

FGF23 (intact) human ELISA 

Features and Benefits 

• RELIABLE and FULLY VALIDATED for plasma samples – according to ICH Q2

• SERUM, URINE and CC SUPERNATANT are compatible with this ELISA

• FAST ONE-STEP ELISA – only 3.5 h total incubation time

• PLASMA BASED STANDARDS and CONTROLS INCLUDED – for biologically reliable data

• CHARACTERIZED MONOCLONAL ANTIBODIES – high specificity and sensitivity guaranteed
• GOOD CORRELATION with existing ELISA methods

Why FGF23 ELISA from Biomedica?

√ Proprietary products – developed and manufactured in our European facilities

√ Excellent stability in all matrices after sample collection

√ CE registration in progress

Please click below for:

– Assay Validation Data
– Instruction For Use
– Biomedica FGF23 Info Leaflet
– Product Website

Related Product:  
FGF23 (C-terminal) ELISA

Meet Biomedica Immunoassays at poster P95 “Detection of intact FGF23 using a novel well-characterized ELISA” to learn more about new FGF23 (intact) human ELISA and to discuss your research projects!

Useful links:

Scientific Program

FGF23 (intact) human ELISA

 

BIOMEDICA is happy to announce the launch of its:

FGF23 (intact) human ELISA  Features and Benefits  • RELIABLE and FULLY VALIDATED for plasma samples – according to ICH Q2 • SERUM, URINE and CC SUPERNATANT are compatible with this ELISA • FAST ONE-STEP ELISA – only 3.5 h total incubation time • PLASMA BASED STANDARDS and CONTROLS INCLUDED – for biologically reliable data • CHARACTERIZED MONOCLONAL ANTIBODIES – high specificity and sensitivity guaranteed • GOOD CORRELATION with existing ELISA methods Why FGF23 ELISA from Biomedica? √ Proprietary products – developed and manufactured in our European facilities √ Excellent stability in all matrices after sample collection √ CE registration in progress Please click below for: – Assay Validation Data – Instruction For Use – Biomedica FGF23 Info Leaflet – Product Website Related Product:   FGF23 (C-terminal) ELISA

Göbel A. et al., J Bone Oncology, 2019; 16: 100237. Full publication.

SEMAPHORIN 4D is a soluble and membrane-bound protein

that plays important roles in physiologic processes such as vascular growth, tumor progression, and immune cell regulation.

Related literature:

The Role of Semaphorin 4D in Bone Remodeling and Cancer Metastasis.
Lontos K et al., Front Endocrinol, 2018; 9:322. Full publication.

A high-sensitivity enzyme immunoassay for the quantification of soluble human semaphoring 4D in plasma.
Laber A et al., Anal Biochem, 2019; 574:15-22. Full publication.

Did you know?

Soluble Semaphorin 4D can easily be quantified with the Biomedica SEMA4D ELISA

√ HIGHLY SPECIFIC – antibodies bind with high affinities to conformational epitopes in the sema domain

√ ACCURATE – successful validation according to FDA guidelines

√ RELIABLE – 7 human plasma based standards and 2 controls for biologically reliable data

√ LOW SAMPLE VOLUME – only 10 µl / well required

√ Plasma is the suitable matrix for reproducible quantification of sSEMA4D

May 11 – 14, 2019

Meet Biomedica Immunoassays at the ECTS Congress in Budapest – booth # 12 – to learn more about our soon to be launched new assay and to discuss your research projects!
In addition to having a booth, we will present the following posters:

• Development and characterization of an extraction-free human CGRP sandwich ELISA

• Novel ELISA for the detection of intact FGF23

Useful links:

Scientific Program 
ECTS Homepage

May 9 – 11, 2019

Meet Biomedica Immunoassays at the Osteoporoseforum in St. Wolfgang to learn more about our soon to be launched new assay and to discuss your research projects!

• intact FGF23 ELISA
• C-terminal FGF23 ELISA
• bioactive Slcerostin ELISA
  
  

Useful links:

Scientific Program 

C-type natriuretic peptide (CNP), a small peptide hormone, plays a crucial role in linear growth. The growth plate is a major contributor to circulating CNP products in the immature skeleton. Its bio-inactive aminoterminal  propeptide (NTproCNP) is easily measurable in plasma, and levels reflect the rate of CNP biosynthesis.

Plasma C-Type Natriuretic Peptide: Emerging Applications in Disorders of Skeletal Growth.
Espiner E et al.,Horm Res Paediatr,2019;7;90(6):345-357.

Did you know? 

NT-proCNP can easily be quantified with the Biomedica 2^nd generation NT-proCNP ELISA (cat.no. BI-20812)

√ HIGH SENSITIVITY – 0.7 pmol/l (= 3.49 pg/ml)

√ EASY – direct measurement – no concentration step

√ LOW SAMPLE VOLUME – only 20 µl / well required

√ ACCURATE – successful validation according to FDA guidelines

√ RELIABLE – 7 human plasma based standards and 2 controls for biologically reliable data

√ High cross-reactivity with rat NT-proCNP

Literature: 

• Dynamic response of C-type natriuretic peptide and its aminoterminal propeptide (NTproCNP) to growth hormone treatment in children with short stature. 
  Olney RC et al.,Clin Endocrinol,2016;85(4):561-8.
  
  
• Serum NT-proCNP levels increased after initiation of GH treatment in patients with achondroplasia/hypochondroplasia. 
  Kubota T et al.,Clin Endocrinol,2016;84(6):845-50.
  
  
• Rats deficient C-type natriuretic peptide suffer from impaired skeletal growth without early death.
  Fujii T et al.,PloS One,2018;13(3):e0194812.

WORLD CONGRESS ON OSTEOPOROSIS, OSTEOARTHRITIS AND MUSCULOSKELETAL DISEASES

April 4 – 7, 2019

Meet Biomedica Immunoassays at poster P676 “Novel ELISA Allows Accurate Quantification of Intact Fibroblast Growth Factor 23 (FGF23) in Serum and Plasma” to learn more about our soon to be launched new assay and to discuss your research projects!

Useful links:

Scientific Program 

WCO-IOF-ESCEO Homepage

 

Together with our partner Immundiagnostik from Bensheim, Germany, we presented Biomedica Immunoassays at the Osteologie congress in Frankfurt.

We proudly presented our soon to be launched ELISA for the quantitative measurement of intact FGF23 in a talk and generated a lot of interest in the test. The poster introducing our new bioactive Sclerostin ELISA, a test that specifically detects Sclerostin at its receptor binding site, was visited by many congress participants and was discussed a lot. Furthermore, a poster introducing our soluble Semaphorin 4D ELISA, a factor promoting skeletal metastasis, was presented the field of osteo-oncology.

We greatly enjoyed this interesting congress and look forward to next year’s Osteologie congress taking place in Salzburg, Austria!

Wir freuen uns, mit unserem Partner Immundiagnostik vom 8.-10.3.2018 bei der Osteologie in Dresden auszustellen und Sie bei Stand # 25 begrüßen zu dürfen.

Produkthighlights:

NT-proBNP ELISA – kardialer Biomarker zur Risikokontrolle bei NSAR Therapie

bioactive Sclerostin ELISA – Inhibitor des Wnt-Signalweges

FGF23 (C-terminal) ELISA auch für Serum – Regulator des Phosphatstoffwechsels

Für einen Termin mit Biomedica’s Team für wissenschaftliche Produktspezialisten – Dr. Gabriela Berg und Dr. Annegret Bitzer – kontaktieren Sie uns bitte per e-mail.

Weitere Informationen zu Biomedica’s Biomarker Assays:

Bone Metabolism
Cardiovascular
Nephrology

Biomedica Analytical Testing Service

Link zu Immundiagnostik und zur Osteologie 2018.

Visit Biomedica at the FCVB at the Austria Center Vienna from April 20-22, booth #A3, to learn about Biomedica’s new biomarker ELISAs and to discuss your research projects:

Product Highlights:

proANP ELISA
NT-proBNP ELISA
NT-proCNP ELISA
(Big) Endothelin ELISA
FGF23 (C-terminal) ELISA
soluble Semaphorin 4 D ELISA

Additional information on Biomedica’s Biomarker Assays:

Bone Metabolism
Cardiovascular
Nephrology

Biomedica Analytical Testing Service

Useful links:

Scientific Programme FCVB 2018

FCVB 2018 Congress Website

ERA-EDTA 2018, May 24-27
Bella Center, Copenhagen, DK

ECTS 2018, May 26-29
VCC, Valencia, ES

Product Highlights:

bioactive Sclerostin ELISA
FGF23 (C-terminal) ELISA
Endostatin ELISA
soluble Semaphorin 4 D ELISA
total soluble Neuropilin-1 ELISA

Additional information on Biomedica’s Biomarker Assays:

Bone Metabolism
Cardiovascular
Nephrology

Biomedica Analytical Testing Service

Useful links:

ERA-EDTA 2018 Congress Website

ECTS 2018 Congress Website

Biomedica features bioactive Sclerostin ELISA and FGF23 ELISA

Biomedica is happy to exhibit at the ASBMR Annual Meeting in Montreal, Canada, from Sept 28 – Oct 1, booth # 708.

As a leading supplier of fully validated ELISA kits for clinical research of bone metabolism diseases Biomedica will present the new bioactive Sclerostin ELISA and some preliminary launch information on the mouse Periostin ELISA and intact FGF23 ELISA.

Visit our team at Biomedica’s booth # 708 to discuss your research and learn more about Biomedica and its product offers. Click on the products for detailed product information on:

bioactive Sclerostin ELISA
DKK-1 ELISA
OPG ELISA
free sRANKL ELISA
C-terminal FGF23 ELISA*
Periostin ELISA
soluble Semaphorin 4D ELISA
total soluble Neuropilin-1 ELISA
osteomiR – miRNA bone biomarker
*: not available in the USA

Meet us at the posters:

• Serum Circulating MicroRNAs as a Novel Biomarker for Osteoporotic Vertebral Fractures [SUN-0718]
• Validated and in-depth characterized sandwich ELISA for the quantification of mouse periostin [SUN-0865]
• Circulating miRNAs are associated with higher tibial cortical porosity in postmenopausal osteoporotic women with history of osteoporotic fractures [LB SUN-1148]
• Sandwich Immunoassay for the Specific Detection of Circulating Bioactive Sclerostin in comparison with other Sclerostin ELISA [MON-0724]

Meet Dr. Matthias Hackl from our partner TAmiRNA:

• Bone Turnover Marker Interest Group meeting [SUN 7:15pm, room 520 C]

Meet us at poster #P163 to learn about our C-terminal FGF23 ELISA and our nephrology product line!

From 27th-30th September, Biomedica will participate at the Annual Congress for German Nephrology taking place at the Estrel Convention Center in Berlin. The congress is hosted by the German Society for Nephrology (Deutsche Gesellschaft für Nephrologie, DGfN), which celebrates its 10th anniversary this year.

According to the DGfN, between four and six million Germans live with reduced kidney function. 80,000 of these patients are currently being treated with dialysis. Another 25,000 patients are under medical surveillance after a successful kidney transplant. Therapy for kidney diseases is cost-intensive; treatment for an average dialysis patient amounts to 40,000 Euros per year, amounting to 3 billion Euros health care costs annually. For more information go to http://www.die-nephrologen.de/fakten.html.

To ameliorate current treatment regimens and bring innovative technology to the clinic, the DGfN supports cooperation between ambulant and stationary clinicians and promotes the development of innovative and coordinated strategies to tackle the challenge of improving early diagnosis and long-term treatment of patients with kidney diseases.

One important aspect of improving outcomes is to stratify risk and detect diseases in an early stage. For this reason, Biomedica specialises in developing high-quality biomarker ELISAs for clinical research and application.

As our contribution to the scientific programme of the Kongress Für Nephrologie 2018, Biomedica will be presenting a poster about our C-terminal FGF-23 ELISA kit, a biomarker that has been linked to the clinical outcomes in both acute kidney injury and chronic kidney disease.

Dr. Annegret Bitzer, one of our Biomedica Product managers, is going to present the C-terminal FGF-23 poster (Poster #P163) on Friday 28th September from 2-3:30 pm, and will be happy to chat with you about the clinical significance of intact FGF-23 in kidney disease, as well as about the biomarkers in our innovative nephrology product line, which includes:

Human and mouse/rat Endostatin ELISAs
C-terminal FGF-23 ELISA
Bioactive Sclerostin ELISA
Osteoprotegerin ELISA
Total soluble Neuropilin-1 ELISA
Anti-C4d Antibodies

Coming soon:

Vanin-1 ELISA
intact FGF23 ELISA

We look forward to meeting you at the Congress!

Pricket TCR et al. show in their publication “C-Type Natriuretic Peptides in Coronary Disease” that “in contrast to the close association of NT-proBNP with cardiac function, and predictive value for outcome after myocardial infarction, plasma NT-proCNP (T-terminal C-type Natriuretic Peptide) is highly correlated with renal function and is an independent predictor of mortality and cardiac readmission in individuals with unstable angina.”

C-type Natriuretic Peptides in Coronary Disease

C-Type Natriuretic Peptides in Coronary Disease
Prickett TCR et al., Clin Chem, 2017; 63(1):316-324

Biomedica recently launched a novel validated NT-proCNP ELISA assay to support clinical research:

• EXTENSIVELY VALIDATED for clinical samples
• RELIABLE – 7 human serum based standards and 2 controls for biologically reliable data
• Excellent stability in all matrices after sample collection
• EASY – conventional 96-well format

For detailed information please click corresponding links:

BI-20812 NT-proCNP ELISA IFU
BI-20812 NT-proCNP ELISA Validation Data
BI-20812 NT-proCNP ELISA MSDS

Related publications

Circulating C-type natriuretic peptide and its relationship to cardiovascular disease in the general population.

Sangaralingham SJ, McKie PM, Ichiki T, Scott CG, Heublein DM, Chen HH, Bailey KR, Redfield MM, Rodeheffer RJ, Burnett JC Jr. Hypertension. 2015. 65(6):1187-94. PMID: 25895587.

 

Abstract

C-type natriuretic peptide (CNP) is an endothelium-derived peptide that is released as a protective mechanism in response cardiovascular injury or disease. However, no studies have investigated circulating CNP, identifying clinical factors that may influence CNP and its relationship to cardiovascular disease in the general population. We studied 1841 randomly selected subjects from Olmsted County, MN (mean age, 63±11 years; 48% men). Plasma CNP was measured by a well-established radioimmunoassay and echocardiography, clinical characterization, and detailed medical record review were performed. We report that CNP circulates at various concentrations (median, 13 pg/mL), was unaffected by sex, was weakly associated by age, and that highest quartile of CNP identified a high-risk phenotype. Subjects with CNP in the highest quartile were associated with increased risk of myocardial infarction (multivariable-adjusted hazard ratio, 1.51; 95% confidence interval, 1.09-2.09; P=0.01) but not heart failure, cerebrovascular accidents, or death during a follow-up of 12 years. Addition of the highest quartile of CNP to clinical variables led to a modest increase in the integrated discrimination improvement for risk of myocardial infarction. In a large community-based cohort, elevated circulating CNP identified a high-risk phenotype that included cardiovascular comorbidities and left ventricular dysfunction, and provided evidence that highest concentrations of CNP potentially has prognostic value in predicting future risk of myocardial infarction. Together, these data from the general population highlight the potential value of CNP and support the need for additional studies to evaluate whether mechanisms regulating CNP could improve outcomes.

 

Semaphorin 4D is widely studied for its role in neural connectivity, vascularization, cell migration, the immune response, tumour progression, and bone remodeling.

Areas of interest: osteology, oncology, immunology, neurology

Semaphorin 4D ELISA for clinical samples

Biomedica offers a highly specific soluble Semaphorin 4D (sema4D) ELISA to support clinical research. The Semaphorin 4D ELISA is validated with real clinical samples for various sample matrices like serum or plasma and cell culture supernantants.

• GUARANTEED PERFORMANCE – rigorous validation and QC for plasma samples in clinical trials
• HIGHLY SPECIFIC – characterized antibodies and reagents
• REPRODUCIBLE – specific analysis of soluble non-shed SEMA4D
• RELIABLE – 7 human plasma based standards and 2 controls for biologically reliable data
• LOW SAMPLE VOLUME – only 10 µl / well required
• PROPRIETARY PRODUCT – in-house R&D and production

For detailed information please click corresponding links:

BI-20405 soluble Semaphorin product website
BI-20405 soluble Semaphorin 4D ELISA IFU
BI-20405 soluble Semaphorin 4D ELISA VAlidation Data
BI-20405 soluble Semaphorin 4D ELISA MSDS

Biomedica ELISA Service Quotation Form

Related literature

Semaphorin 4D as a guidance molecule in the immune system.

Kuklina E. Int Rev Immunol. 2021;40(4):268-273. doi: 10.1080/08830185.2021. PMID: 33787446.

 Abstract

Semaphorin 4D (Sema4D) is a classic member of the semaphorin family involved in axonal guidance processes. The key effects of Sema4D in neurons are mediated by high affinity plexin receptors and are associated with cytoskeleton rearrangement, leading to growth cone collapse or regulation of cell migration. Along with this, the semaphorin is widely represented in the immune system and has a pronounced immunoregulatory activity. The involvement of Sema4D in the control of immune cell migration was shown almost twenty years ago, in one of the first studies of semaphorin. The emergence of such work was quite predictable, since the most well-known effects of Sema4D outside the immune system were associated precisely with the control of cell motility. However, after identification of CD72 as a specific Sema4D receptor in the immune system, studies of the immunoregulatory activity of semaphorin focused on its CD72-dependent effects unrelated to cytoskeleton rearrangement, and this trend continues up to now. Nevertheless, a number of recent studies demonstrating the presence of plexin receptors for Sema4D in the immune system forces us to return to the question of whether this semaphorin can play its classic role of a guidance molecule in relation to immune cells too. The review discusses Sema4D involvement in the control of immune cell migration, as well as the mechanisms of these effects and their potential contribution to the development and function of immune system.

 

Cost-utility analysis of fracture risk assessment using microRNAs compared to standard tools and no monitoring in the Austrian female population.

E.Walter, H. Dellago, J. Grillari, H.P. Dimai, M. Hackl, Bone, Volume 108, 2018, pages 44-54. Click link for full-text publication.

First comprehensive attempt to model the cost-effectiveness of circulating microRNAs for bone fracture risk assessment in comparison with DXA and FRAX®

The results demonstrate that the osteomiR™ kit can be a cost-effective alternative to established risk assessment strategies.

• osteomiR™ utilization can reduce fracture incidence in postmenopausal women
• osteomiR™ represents a cost-effective alternative to DXA, FRAX®
• Deterministic and probabilistic senstitivity analyses confirm robustness of the model

For detailed information please click corresponding links:

osteomiR™ microRNA biomarker product website

osteomiR™ key publications

osteomiR™ FAQs

microRNA customized services

microRNA customized services FAQs

Biomedica microRNA Service Quotation Form

The only Sclerostin ELISA that utilizes specific EPITOPE MAPPED ANTIBODIES enabling the analysis of bioactive Sclerostin in clinical samples. 

Bioactive Sclerostin ELISA (cat.no. BI-20472) Assay Highlights:

• HIGHLY SPECIFIC and DEFINED: capture antibody directed against Sclerostin’s bioactive site. Learn more
• RELIABLE: human serum based calibrators and controls, rigorously validated
• LOW SAMPLE VOLUME: 20 µl / well
• QUICK: total incubation time 3.5 h

First bioactive Sclerostin ELISA for clinical samples

 

Areas of interest: osteoporosis, cancer induced bone diseases, rheumatoid arthritis, chronic inflammation, kidney diseases, therapy monitoring of anabolic treatment.

 

For detailed information please click corresponding links:

BI-20472 bioactive Sclerostin product website
BI-20472 bioactive Sclerostin ELISA IFU
BI-20472 bioactive Sclerostin ELISA Validation Data
BI-20472 bioactive Sclerostin ELISA MSDS

 

RELATED PUBLICATIONS

Circulating bioactive sclerostin levels in an Austrian population-based cohort. Kerschan-Schindl K, Föger-Samwald U, Gleiss A, Kudlacek S, Wallwitz J, Pietschmann P. Wien Klin Wochenschr. 2022 Jan;134(1-2):39-44. doi: 10.1007/s00508-021-01815-0. Epub 2021 Feb 5. PMID: 33544208; PMCID: PMC8813720.

Abstract

Two new publications using TAmiRNA’s osteomiR™ kit and microRNA services to investigate the role of microRNAs in osteoporosis:

Bone-related circulating microRNAs miR-29b-3p, miR-550a-3p and miR-324-3p and their association to bone microstructure and histomorphometry. X. Feichtinger, C. Muschitz, P. Heimel et al., Scientific Reports, Vol 8, Article Number : 4867 (2018). Click link for full-text publication.

Bone-related circulating miRNAs are signifcantly associcated to dynamic processes of bone, reflected by bone histomorpometry.

Altered microRNA Profile in Osteoporosis Caused by Impaired WNT Signaling. RE Mäkitie, M Hackl, R Niinimäki et al., J. Clin Endocrinol Metab. 2018 Mar 1 [Epub ahead of print]. Click link for abstract.

Circulating miRNA pattern reflecting WNT1 Mutation Status provide novel insights into the mode of Action of WNT1 osteoporosis.

For detailed information please click corresponding links:

osteomiR™ microRNA biomarker product website
osteomiR™ key publications osteomiR™ FAQs

microRNA customized services
microRNA customized services FAQs
Biomedica microRNA Service Quotation Form

Biomedica is happy to introduce our novel Neuropilin-1 ELISA that measures total human soluble NRP1 in biological samples utilizing specific EPITOPE MAPPED ANTIBODIES.

Assay Highlights:

• HIGHLY SPECIFIC and DEFINED – epitope mapped antibodies
• RELIABLE: human serum based calibrators and controls, rigorously validated
• LOW SAMPLE VOLUME: 10 µl / well
• QUICK: total incubation time 4 h
• PROTOCOLS available for urine, cc supernatants and non-human samples

Novel Neuropilin-1 ELISA

Areas of interest: neurological disorders, oncology, nephrology, osteology, cardiology

For detailed information please click corresponding links:

BI-20409 total soluble Neuropilin-1 product website
BI-20409 total soluble Neuropilin-1 ELISA IFU
BI-20409 total soluble Neuropilin-1 ELISA Validation Data
BI-20409 total soluble Neuropilin-1 ELISA MSDS

Biomedica ELISA Service Quotation Form

Related literature

Serum concentrations of neuropilin-1 in women with endometriosis. Barberic M, Pavicic Baldani D, Rogic D, Kralik S.Scand J Clin Lab Invest. 2020 Jul;80(4):271-276. doi: 10.1080/00365513.2020.1728785. Epub 2020 Feb 18. PMID: 32069143.

Abstract